Latanoprostene bunod is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprostene Bunod was developed by Nicox.
The API has now reached off-patent status, after being launched in 2017.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Latanoprostene Bunod and many others, contact info@pharmacheminvestor.com